(MENAFN- GlobeNewsWire - Nasdaq) Integration of CRISPR Gene Editing, AI-Based Drug Screening, and Patient-Derived Organoid Platforms Reshaping Biomedical Research and Pharmaceutical Drug Discovery Globally.Austin, United States, March 16, 2026 (GLOBE NEWSWIRE) -- Organoids and Spheroids Market Size & Growth Analysis:
"According to SNS Insider, The Organoids and Spheroids Market was valued at USD 1.76 Billion in 2025 and is projected to reach USD 11.94 Billion by 2035, reflecting a compound annual growth rate (CAGR) of 21.13% from 2026 to 2035."
The global organoids and spheroids market is experiencing rapid expansion, driven by the fundamental limitations of conventional two-dimensional cell culture models, which fail to replicate complex human tissue interactions critical for disease modeling and drug screening. Organoid and spheroid technologies address this gap by enabling in vitro development of organ-like structures that closely mimic human physiology, making them indispensable tools for pharmaceutical R&D, regenerative medicine, and stem cell research.
![Organoids And Spheroids Market]()
Get a Sample Report of Organoids and Spheroids Market:
The rising prevalence of chronic diseases including cancer, neurological disorders, and liver disease combined with growing investments in translational medicine and life science research, continues to accelerate adoption. The integration of advanced technologies such as CRISPR gene editing, high-content imaging, AI-based drug screening, and microfluidic organ-on-chip platforms is further strengthening the utility of these models across biotechnology and pharmaceutical applications. In March 2025, leading pharmaceutical companies reported that organoid-based screening platforms reduced early-stage drug development timelines by nearly 30%, underscoring the commercial value of 3D cell culture technologies.
The U.S. Organoids and Spheroids Market was valued at USD 0.61 Billion in 2025 and is expected to reach USD 3.94 Billion by 2035, growing at a CAGR of 20.55%. The U.S. market is underpinned by robust biotechnology infrastructure, substantial federal funding for stem cell research, and high-volume clinical research activity in personalized medicine and precision oncology. Strong collaboration between academic centers and biotech startups continues to accelerate adoption of next-generation 3D cell culture platforms.
Major Players Listed in this Report:
Thermo Fisher Scientific Corning Incorporated STEMCELL Technologies Merck KGaA Lonza Group PromoCell GmbH Greiner Bio-One International 3D Biotek InSphero AG HUB Organoids DefiniGEN AMS Biotechnology PeproTech Takara Bio Cellesce Ltd Axol Bioscience Reprocell Inc. ScienCell Research Laboratories TissUse GmbH CN Bio Innovations
Segmentation Analysis
By Type: The organoids segment held the dominant share of 57.42% in 2025, owing to its extensive applications in neural, hepatic, and intestinal disease modeling, cancer research, and organ development studies. Spheroids are projected to register the fastest CAGR of 22.16% during the forecast period, driven by their increasing utility in high-throughput drug screening, multicellular tumor microenvironment modeling, and advancements in automated microfabrication and microplate spheroid formation techniques.
By Application: Drug toxicity and efficacy testing commanded the largest application share of 28.37% in 2025, as pharmaceutical companies increasingly rely on organoid and spheroid systems to evaluate drug-human tissue interactions ahead of clinical trials. Personalized medicine is anticipated to grow at the highest CAGR of 23.41%, fueled by the rising use of patient-derived organoids in precision oncology, rare disease treatment planning, and genomic sequencing-integrated therapeutic development.
By End Use: Biotechnology and pharmaceutical industries accounted for the largest share of 52.64% in 2025, reflecting extensive adoption across drug discovery, toxicology studies, and biomarker identification workflows. Academic and research institutes are expected to grow at the fastest CAGR of 21.95%, supported by government funding programs, stem cell research initiatives, and expanding collaborations between universities and biotech companies.
Need Any Customization Research on Organoids and Spheroids Market, Enquire Now:
Organoids and Spheroids Market Segmentation
By Type
Organoids By Type Neural organoids Hepatic organoids Intestinal organoids Other organoid types
By Method General submerged method for organoid culture Crypt organoid culture techniques Air Liquid Interface (ALI) method Other organoid methods
By Source Primary tissue Stem cells
Spheroids By Type Multicellular tumor spheroids Neurospheres Mammospheres Hepatospheres
By Method Micropatterned plates Low cell attachment plates Hanging drop method Other spheroid methods
By Source Cell line iPSC-derived cells
By Application
Developmental Biology Personalized Medicine Regenerative Medicine Disease Pathology Studies Drug Toxicity & Efficacy Testing
By End-use
Biotechnology and pharmaceutical industries Academic & Research Institutes Hospitals and Diagnostic centers
Regional Insights
North America dominated the global organoids and spheroids market in 2025 with a 42.18% revenue share, driven by a robust biotechnology ecosystem, high research funding, and strong adoption of advanced cell culture technologies. The U.S. leads within the region through deep integration of clinical research, biotech-academia collaboration, and continued federal investment in stem cell and regenerative medicine programs.
Europe holds the second-largest market position, with countries including Germany, the UK, and the Netherlands investing substantially in organoid-based disease modeling, drug discovery, and government-funded biotechnology innovation programs.
The Asia Pacific market is expected to register the fastest growth with a CAGR of 22.87% during the forecast period. Rapid expansion of biotechnology industries, growing demand for advanced drug discovery platforms, and improving life sciences infrastructure across China, Japan, South Korea, and India are key regional growth catalysts. Latin America and the Middle East & Africa markets are witnessing gradual growth through increasing biomedical research investments and international biotechnology collaborations.
Recent Developments
In January 2025, Thermo Fisher Scientific launched a new organoid culture kit designed to accelerate patient-derived tumor organoid development for oncology drug screening applications. In March 2025, STEMCELL Technologies introduced a new intestinal organoid culture system aimed at improving long-term organoid growth consistency and reproducibility for research applications. In October 2024, Corning Incorporated expanded its 3D cell culture portfolio with advanced spheroid microplates engineered for high-throughput drug screening workflows.
Organoids And Spheroids Market Report Scope
1. Introduction
2. Executive Summary
3. Market Overview
4. Statistical Insights & Trends Reporting
5. Organoids And Spheroids Market Segmental Analysis & Forecast, By Type
6. Organoids And Spheroids Market Segmental Analysis & Forecast, By Application
7. Organoids And Spheroids Market Segmental Analysis & Forecast, By End-use
8. Organoids And Spheroids Market Segmental Analysis & Forecast, By Region
9. Competitive Landscape
10. Analyst Recommendations
11. Assumptions
12. Disclaimer
13. Appendix
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us:
Rohan Jadhav - Principal Consultant
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email:...
Comments
No comment